Insights Into Degenerative Aortic Valve Disease  by Goldbarg, Seth H. et al.
T
p
b
v
h
h
v
c
d
e
i
t
a
n
g
t
t
b
t
r
a
l
h
D
F
H
M
a
Journal of the American College of Cardiology Vol. 50, No. 13, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PSTATE-OF-THE-ART PAPER
Insights Into Degenerative Aortic Valve Disease
Seth H. Goldbarg, MD, Sammy Elmariah, MD, Marc A. Miller, MD, Valentin Fuster, MD, PHD
New York, New York
Despite the dramatic decline of rheumatic heart disease over the past 5 decades, there has not been a concor-
dant decline in the prevalence of valvular heart disease. Degenerative aortic valve disease (DAVD) has become
the most common cause of valvular heart disease in the Western world, causing significant morbidity and mor-
tality. No longer considered a benign consequence of aging, valve calcification is the result of an active process
that, much like atherosclerotic vascular disease, is preceded by basement membrane disruption, inflammatory
cell infiltration, and lipid deposition and is associated with diabetes, hypercholesterolemia, hypertension, and
tobacco use. These realizations, in addition to pathological insights gained from emerging imaging modalities,
have lead to the exploration of a variety of therapeutic interventions to delay or prevent the progression of
DAVD. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, angiotensin-converting enzyme, and matrix
metalloproteinase have all been studied as potential disease modifiers. Moreover, tissue engineering, aided by
emerging stem cell technology, holds immense potential for the treatment of valvular heart disease as adjuncts
to surgical interventions. Here we review the epidemiology and pathophysiology of DAVD, in addition to highlight-
ing emerging therapeutic interventions for this growing problem. (J Am Coll Cardiol 2007;50:1205–13)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.024c
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the prevalence of valvular heart disease in the adult U. S.
opulation at the beginning of the twenty-first century has
een estimated at more than 5 million (1). Degenerative
alve disease, now the most common etiology of valvular
eart disease in industrialized nations (2,3), is an emerging
ealth problem with broad consequences (Fig. 1). Aortic
alve disease is the third most common cause of cardiovas-
ular disease, and the prevalence of degenerative aortic valve
isease (DAVD) rises as life expectancy increases. An
stimated 95,000 valve procedures are performed each year
n the U. S., and aortic valve disease is responsible for more
han 25,000 annual deaths (4). In the Euro Heart Survey,
ortic stenosis was the most frequent etiology of single
ative left-sided valve disease and was predominantly de-
enerative in origin (Fig. 2) (3,5).
Characterized by progressive dystrophic calcification of
he valve cusps (6), the early stages of DAVD are similar to
he active inflammatory process of atherosclerosis including
asement membrane disruption, inflammatory cell infiltra-
ion, lipid deposition and calcification (7,8). The clinical
isk factors associated with the genesis and progression of
therosclerosis, including age, gender, diabetes, low-density
ipoprotein (LDL) cholesterol, hypertension, and smoking
ave been implicated in the development of DAVD (9,10).
espite multiple common risk factors, a discrepancy in
rom the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and
enry R. Kravis Cardiovascular Health Center, The Mount Sinai School of
edicine, New York, New York.(
Manuscript received April 26, 2007; revised manuscript received June 4, 2007,
ccepted June 12, 2007.oexisting prevalence exists between calcific aortic stenosis
nd coronary artery disease. Only one-half of patients with
evere calcific aortic stenosis have significant coronary artery
isease, and most patients with coronary artery disease do
ot have aortic stenosis (11). This discrepancy highlights
he fact that despite the shared risk factors between calcific
ortic valve disease and coronary artery disease, additional
actors contribute to the development of DAVD.
athophysiologic Insights on DAVD
ndothelial function. Unique structural and functional
omponents of valvular endothelium contribute to the
egenerative processes underlying valvular calcification (12).
he aortic valve is chronically exposed to complex shear
orces. Evidence has shown that directional shear stress is
enerally responsible for arterial endothelial alignment in
ivo (13). Cultured aortic endothelial cells align perpendic-
lar to flow direction, in contrast to the typical parallel
lignment to flow seen in other endothelial culture studies
14). Calcification occurs primarily on the aortic side of the
ortic valve leaflets, where flow is most turbulent, suggesting
hat shear stress and its interaction with valvular endothe-
ium plays a role in calcification (Fig. 3).
omparison to atherosclerotic disease. Degenerative aor-
ic valve disease shares many characteristics with atheroscle-
otic disease. The early lesion of both vascular and calcific
ortic disease involves basement membrane disruption;
acrophage and T-lymphocyte migration; and lipid infil-
ration, notably apolipoprotein (apo) B, apo(a), and apoE
Fig. 4) (7,15–17). Ensuing inflammation causes activation
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Degenerative Aortic Valve Disease September 25, 2007:1205–13of myofibroblasts, release of cy-
tokines such as tumor necrosis
factor (TNF)-alpha and trans-
forming growth factor (TGF)-
beta-1, and expression of matrix
metalloproteinase (MMP). Cy-
tokine release helps to initiate
the calcification process in both
valvular and vascular tissues by
up-regulating MMP and bone
morphogenic protein (BMP)
expression, which in turn pro-
mote osteogenic phenotypes
within both tissue types (Fig. 5)
(18–28).
However, specific cellular and
genetic mechanisms of degener-
ation affect the aortic valve sub-
strate. In addition to the unique
milieu created by shear forces at
the valvular level (13), the molec-
ular mechanisms responsible for
valve and vascular calcification
re associated with differential cellular expression. Valves
ack smooth muscle cells, which are an important feature of
therosclerotic lesions in the vasculature (18). In contrast,
alves contain myofibroblasts that proliferate in response to
ecreased nitric oxide levels; angiotensin II; and local
ormones, including tissue growth factor and platelet-
erived growth factor (15).
alcification and bone formation. Calcification is a dis-
inguishing feature of DAVD that relies on bone-regulatory
rotein expression. In a study of explanted valve allografts,
hetty et al. (19) found that heavy calcification was prom-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BMP  bone morphogenic
protein
CMR  cardiac magnetic
resonance imaging
DAVD  degenerative
aortic valve disease
LDL  low-density
lipoprotein
MMP  matrix
metalloproteinase
MSR  macrophage
scavenger receptor
RANK  receptor activator
of nuclear factor kappa B
TGF  transforming growth
factor
TNF  tumor necrosis
factor
Figure 1 Evolution of Valve Disease in Industrialized Nations
Reprinted with permission from Soler-Soler J, Galve E.
Worldwide perspective of valve disease. Heart 2000;83:721–5.nent in stenotic valves and that calcified regions were
ssociated with osteocalcin and increased bone alkaline
hosphatase expression. The authors examined calcified
alve allografts and found that they expressed the bone-
pecific transcription factor Cbfa-1, osteopontin, and
steonectin, which were not present in normal valves
19). They went on to show that receptor activator of
uclear factor kappa B (RANK) ligand, which is ex-
ressed by osteoblasts and T-cells in areas of active bone
emodeling, was present in calcified valve allograft leaf-
ets. Colocalization of the RANK ligand binding site and
steoprotegerin (a protein that binds to RANK ligand
nd regulates osteoclast activity) confirmed that expres-
ion pattern of the RANK ligand/RANK/osteopotegerin
ystem may have a regulatory role in osteoclastogenesis
nd calcification of human valve allografts (Fig. 5)
19,20).
enetic factors. Genetic factors play a definitive role in
he risk of DAVD and provide a link to the pathobiology
Figure 2 Etiology of Aortic Stenosis
From the Euro Heart Survey
Modified, with permission, from Iung et al. (3).
Figure 3 Aortic Valve Endothelial Heterogeneity
Regional and local forces affect endothelial
alignment. Reprinted, with permission, from Davies et al. (12).
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September 25, 2007:1205–13 Degenerative Aortic Valve Diseasef valve calcification. The NOTCH1 transcriptional
actor regulates osteogenic differentiation as well as valve
evelopment. Functional mutations in the gene may
ncrease osteoblast formation and calcification and alter
he structural development of the valve (Fig. 5) (21). In
act, gene mutations in NOTCH1 were found in 2
ohorts of patients with valvular anomalies and severe
alvular calcification (22).
Somatic cells reaching a certain age enter into replica-
ive senescence, a nondividing state associated with
Figure 4 Diseased Valvular Endothelium
Diseased endothelium exhibits nonlaminar flow, low-density lipoprotein (LDL) depo
Differential expression of cytoskeletal elements promotes a valvular phenotype. BM
Figure 5 Interplay of Lipids and Inflammation With Genetics on
IL  interleukin; OPG  osteoprotegrin; RANK  receptor activator of nuclear fact
TNF  tumor necrosis factor; other abbreviations as in Figure 4. Modified, with peertain morphologic and cellular changes (23). For ex-
mple, telomeres shorten as cells replicate (24). Kurz et
l. (25) recently hypothesized that aortic valve cusps,
hich are under constant mechanical stress and thus in
eed of constant cell turnover, may contain senescent
ells with decreased telomere length. After examining
93 older patients with and without aortic stenosis, the
esearchers found that shorter leukocyte telomere length
as in fact associated with the presence of calcific aortic
isease (Fig. 5).
macrophage infiltration, and matrix metalloproteinase (MMP) expression.
bone morphogenic protein. Modified, with permission, from Fuster et al. (18).
enerative Aortic Valve Disease
pa B;
on, from O’Brien (21).sition,
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Degenerative Aortic Valve Disease September 25, 2007:1205–13ole of New Imaging Technologies
n addition to the ability to diagnose and quantify aortic
tenosis, new imaging modalities may better define the
athologic pathways involved in DAVD. Contrast-
nhanced molecular imaging techniques are rapidly emerging
s powerful adjuncts to traditional contrast cardiac magnetic
esonance imaging (CMR). Lipid-based gadolinium-
omplexed nanoparticles can penetrate atherosclerotic
laque, enhancing the ability of CMR to detect and
haracterize atheromatous plaque (26). High-density li-
oprotein gadolinium-nanoparticles that have high affinity
nd greater specificity for atherosclerotic lesions have re-
ently been developed. Studies with these nanoparticles
howed both early enhancement in macrophage-rich
laques and late enhancement of advanced lesions in vivo
27). Labeling gadolinium-containing micelles with specific
ntibodies may increase the specificity of molecular imaging
echniques by targeting areas of atherosclerosis that contain
ertain surface markers. Lipinski et al. (27) used immu-
omicelles linked with a monoclonal antibody for macro-
hage scavenger receptor (MSR)-A, a receptor implicated
n atherosclerosis progression, to enhance ex vivo imaging of
therosclerotic plaque (Fig. 6). They found that both
icelles and immunomicelles were superior to standard-
ontrast agents in vitro and that immunomicelles targeting
he MSR-A receptor in murine apoE knockout aortas
nhanced ex vivo imaging over standard micelles.
Micro-computerized tomography has been utilized to
ssess mineral levels in explanted human heart valves (28).
ajamannan et al. (28) report a characteristic pattern of
alcification in a series of 22 explanted aortic valves, with the
eaviest mineralization occurring near the outer edges of
ach calcified nodule. Micro-computerized tomography re-
ealed the depth and extent of calcification and suggested
hat valve calcification is an active process of bone formation
ssociated with an osteoblast phenotype (Fig. 7). Novel
maging techniques hold significant promise for further
athologic characterization and potential clinical application
hat may bear directly on treatment and outcomes of
Figure 6 Ex Vivo Confocal Microscopy Performed at 100 Mag
The aortas were incubated with control, nitro-2-1,3-benzoxadiazol-4-yl (NBD)-labeled
with 4’,6-diamidino-2-phenylindole (blue) and R-phycoerythrin-labeled anti-CD68 (reAVD.herapeutic Insights for DAVD
isk factor modification. Given the clear relationship
etween systemic atherosclerosis and DAVD (29,30) and
he predilection for patients with cardiovascular risk factors
o develop DAVD (9,31), modification of these risk factors
ppears the most obvious method for preventing or treating
alvular calcification. However, with the exception of lipid
anagement, no clinical trials have addressed whether
nterventions aimed at altering cardiovascular risk factors
uch as hypertension, diabetes, and tobacco use have any
ffect on the progression of DAVD.
MG-CoA reductase inhibitors. 3-hydroxy-3-methyl-
lutaryl-coenzyme A reductase inhibitors (HMG-CoA),
nown as statins, inhibit the rate-limiting step in cholesterol
iosynthesis. Statins have aggressively been studied as a
herapeutic option for DAVD. In addition to lowering lipid
evels, statins also possess pleiotropic mechanisms that may
inder the progression of DAVD.
Statin therapy disrupts many of the inflammatory path-
ays critical for the development of DAVD. Statins signif-
cantly down-regulate the expression of numerous inflam-
atory cytokines, including TGF-beta-1 and TNF-alpha in
ation of Apo-E Knockout Murine Aortas
lles (green), and NBD-labeled immunomicelles (green) and stained
t stains for macrophages. Reprinted, with permission, from Lipinski et al. (27).
Figure 7 Micro-Computerized 3-Dimensional
Reconstruction of the Calcified Aortic Valve
Reprinted, with permission, from Rajamannan et al. (28).nific
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September 25, 2007:1205–13 Degenerative Aortic Valve Diseasealve interstitial cells (32) and the expression of TNF-alpha
n macrophages (33) and endothelial cells (33). Numerous
tatins inhibit the secretion of MMPs from rabbit vascular
mooth muscle cells and macrophages (34). In addition to
ltering the inflammatory milieu in degenerative heart
alves, statins specifically inhibit the calcification process in
itro. Statins were found to down-regulate the expression of
MP-2 and -6 in human aortic valve interstitial cells (32)
nd to inhibit alkaline phosphatase activity, a marker of
steoblastic differentiation, in cell culture models of valve
alcification (32,35). Data suggest that statin effects on valve
alcification are independent of the pleiotropic effects
aused by inhibition of protein prenylation (35) and that
hey may in part be due to attenuation of LDL receptor-
elated protein-5/beta-catenin protein levels (36) and up-
egulation of endothelial nitric oxide synthase (15).
Retrospective clinical trials have shown significant reduc-
ions in the progression of DAVD with statin therapy
37–42). Using echocardiographic measures of aortic steno-
is (38,40–42) and aortic valve calcium scores as determined
y electron-beam computed tomography (37,39), statin
ummary of Retrospective Studies of Medical Therapy in the Preve
Table 1 Summary of Retrospective Studies of Medical Therapy
Study n Patient Characteristics
Retrospective studies
Pohle et al. (37) 104 Patients with coronary and
AV calcification
LD
Aronow et al. (42) 180 Patients with mild AS and
2 echocardiograms
2 yrs apart
LD
Novaro et al. (38) 174 Patients with mild-to-moderate
calcific AS and
2 echocardiograms
12 months apart
St
Shavelle et al. (39) 65 Patients with 2 electron beam
tomography scans
6 months apart
St
Bellamy et al. (40) 156 Patients with AS, mean
transvalvular gradient
10 mm Hg and aortic valve
area 2.0 cm2
St
Rosenhek et al. (41) 211 Patients with aortic jet velocity
2.5 m/s, normal LVEF, no
other valvular lesion with
2 echocardiograms
6 months apart
St
Prospective studies
Cowell et al. (SALTIRE) (43) 155 Calcific AS with aortic jet
velocity 2.5 m/s with
no statin indication
Ra
Moura et al. (RAAVE) (44) 121 Moderate to severe AS with
AV area 1.0 cm2
Ro
odified, with permission, from Rajamannan and Otto (15).
ACE  angiotensin-converting enzyme; AS  aortic stenosis; AV  aortic valve; LDL  low-densherapy appeared to reduce the progression of aortic stenosis sy approximately 50% (Table 1). With some exceptions
37), data suggest that the ability of statins to slow the
rogression of aortic stenosis is likely secondary to pleiotro-
ic effects of statin therapy and not on the lipid-lowering
ffects (38–42).
Data from prospective clinical trials are not as clear
43,44). In the SALTIRE (Scottish Aortic Stenosis and
ipid Lowering Therapy) trial, patients with severe aortic
tenosis (mean valve area  1.03 cm2) were randomized to
tovastatin or placebo; statin therapy failed to halt or reverse
he progression of calcific aortic stenosis (43). However, the
AAVE (Rosuvastatin Affecting Aortic Valve Endothe-
ium) study, a prospective, nonrandomized trial, demon-
trated that in patients with moderate to severe aortic
tenosis (mean valve area  1.23 cm2), treatment with
osuvastatin for elevated serum LDL slowed the progression
f aortic stenosis as compared to patients with normal LDL
evels not needing statin therapy (44). Numerous features of
hese 2 trials may explain the discrepancies between them.
irst, patients with an indication for statin therapy were
xcluded from the SALTIRE trial, whereas in previous
of Calcific Aortic Stenosis
e Prevention of Calcific Aortic Stenosis
udy Groups Parameter Reported Findings
0 mg/dl vs.
130 mg/dl
AV calcium on electron
beam tomography
Lower LDL associated with
slower progression of
AV calcification
5 mg/dl without
vs. LDL 125
l with statin vs.
125 mg/dl
ut statin
Peak transvalvular gradient
on echocardiogram
Lower LDL and statin use
associated with slower
progression of AS
erapy vs. no
therapy
AV area and peak gradient
on echocardiogram
Statin use associated with
slower progression
of AS
erapy vs. no
therapy
AV calcium on electron
beam tomography
Statin use associated with
slower progression of
AV calcification
erapy vs. no
therapy
AV area and mean gradient
on echocardiogram
Statin use associated with
slower progression
of AS
erapy vs. no
therapy; ACE
tor therapy vs.
E inhibitor
Aortic-jet velocity and peak
transvalvular gradient on
echocardiogram
Statins, but not ACE
inhibitors, associated
with slower AS
progression,
independent of LDL
levels
ized to
statin (80 mg)
cebo
Aortic-jet velocity on
echocardiogram and AV
calcification on
computed tomography
No difference between
groups
tatin (20 mg) vs.
bo based on
ine LDL
Progression of AS on
echocardiogram and
improvement in serum
LDL
Rosuvastatin associated
with slower progression
of AS and lower serum
LDL
protein; LVEF  left ventricular ejection fraction.ntion
in th
St
L 13
LDL 
L 12
statin
mg/d
LDL 
witho
atin th
statin
atin th
statin
atin th
statin
atin th
statin
inhibi
no AC
ndom
atorva
vs. pla
suvas
place
baseltudies and in the RAAVE study, statin therapy was
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Degenerative Aortic Valve Disease September 25, 2007:1205–13rescribed specifically for the management of hyperlipid-
mia (38–45). Given this difference in the risk factor profile
f studied patients, it is conceivable that calcific valve disease
ay behave differently in these patient populations (33).
he SALTIRE trial patients had heavily calcified aortic
alves before study enrollment (43). Valve calcification was
ot quantified in the RAAVE study; nevertheless, the
uthors suggest that the burden of valve calcification in
AAVE study patients was likely less than in the
ALTIRE trial (44). Consequently, although statins failed
o halt or reverse the progression of calcific aortic stenosis,
hey may still be able to prevent its development. As shown
y Wu et al. (35), statin therapy inhibits valve calcification
n vitro but stimulates calcification of osteoblasts. As 15% of
atients with end-stage calcific aortic valve disease have
ature lamellar bone with active osteoblasts within their
alve leaflets, it is possible that statins could actually
ccelerate valve calcification in this subset of patients (23).
hus, the stage at which statin therapy is initiated may
ignificantly alter the noted effects. The ongoing prospective
linical trials SEAS (Simvastatin and Ezetimibe in Aortic
tenosis), ASTRONOMER (Aortic Stenosis Progression
bservation: Measuring the Effects of Rosuvastatin), and
TOP-AS (Stop Aortic Stenosis) will help delineate the
atient populations with aortic stenosis that might benefit
rom statin therapy.
ngiotensin-converting enzyme (ACE) inhibitors. The
resence of ACE in diseased calcific valves is a hallmark of
hese lesions. O’Brien et al. (46) found that ACE was
resent in diseased, but not normal aortic valves and that it
as predominantly associated with extracellular apolipopro-
ein B (Fig. 8). Western blotting confirmed that ACE was
resent on normal plasma LDL, suggesting that LDL may
ave been the mechanism of entry of ACE into the
ndothelium. Advanced valve lesions also contain both
ngiotensin II and the angiotensin II receptor AT-1,
Figure 8 ACE in a Human Aortic Valve Lesion
(A) Double immunostaining for macrophages (blue stain) and angiotensin-
converting enzyme (ACE) (red stain) demonstrate that the majority of macro-
phages lack ACE protein (blue stain); most staining is extracellular. A minority
of macrophages contain ACE protein (purple stain). (B) Double immunostain-
ing for macrophages (blue stain) and apolipoprotein B (apoB), the primary
protein of low-density lipoprotein cholesterol particles (brown stain), demon-
strates the presence of extensive extracellular apoB staining, which colocalizes
with extracellular ACE. Original magnification 400. Reprinted, with permis-
sion, from O’Brien et al. (46).ndicating that the renin-angiotensin system plays a signif-cant role in calcific valvular disease (46,47). Retrospective
ata suggests that ACE inhibitor use is associated with
lowed aortic valve calcium accumulation (48), although
hey were not found to inhibit the progression of aortic
tenosis (41). Rosenhek et al. (41) failed to show a beneficial
ffect of ACE inhibitors on progression of aortic stenosis, in
art because of the hemodynamic effects of ACE inhibitors,
hich may obscure the effects on valve stenosis by altering
ow conditions across the valve (15,49). Although the role
f ACE inhibition on the progression of DAVD remains to
e clarified, ACE inhibitors have favorable effects on cardiac
emodeling in aortic stenosis (50).
MP inhibitors. Matrix metalloproteinases are known to
lay a significant role in the vascular remodeling through
heir ability to degrade the extracellular matrix within vessel
alls (Fig. 4) (51). Matrix metalloproteinase-mediated elas-
in degradation has been associated with aortic calcification
52). In cardiac valves, MMPs are thought to help maintain
he integrity and pliability of valve tissue (16); however,
bnormal expression of MMPs, as is caused by inflamma-
ion, subsequently plays a role in abnormal valve remodeling
nd calcification. Emerging data may determine whether
nhibition of MMP activity decreases calcification within
alve tissue as it does within the vasculature.
merging Interventional Therapies
issue engineering. Surgical repair or replacement with
echanical or bioprosthetic valves serves as the therapeutic
nd point in the management of DAVD. Despite improve-
ents in both surgical technique and the design of mechan-
cal valves, the risks of thromboembolism, prosthetic valve
ndocarditis, chronic anticoagulation, and poor hemody-
amic performance remain high in patients receiving valve
rostheses (53). Moreover, bioprosthetic valves, which are
ssociated with less risk of thromboembolism, possess lim-
Figure 9 HE Staining of Native and
Decellularized Porcine Pulmonary Heart Valves
Shown are conduit wall (A) and leaflet (B). Original magnification 400.
(C, D) Native (left) and decellularized (right) porcine pulmonary heart valves,
staining for collagen I and III (green), elastin (red), and deoxyribonucleic acid
(white). Confocal laser scanning microscopy, original magnification 400.
Shown are conduit wall (C) and leaflet (D). Reprinted, with permission, from
Rieder et al. (56). HE  hematoxylin and eosin.
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September 25, 2007:1205–13 Degenerative Aortic Valve Diseaseted longevity and suffer from many of the same degenera-
ive processes that afflict native valves (54).
Tissue engineering has been exploited in an effort to
reate a durable physiologic valve. The oldest approach
elies on the use of acellular matrix xenografts as scaffolds
hat would ultimately become repopulated with cells from
he patient (55). This technique has been hindered by
ailure to decellularize valves without harming the mechan-
cs and cellular responses of the valve matrix, by an inability
o repopulate matrix xenographs in vivo (55), and by
etained immunologic activity of decellularized xenographs
Fig. 9) (56). In vitro repopulation of matrix xenographs is
hought to hold greater potential for success (55). Steinhoff
t al. (57) demonstrated in a sheep model that in vitro
eeding of acellular allogenic heart valve conduits resulted in
n vivo reconstitution of viable heart valve tissue. A second
issue-engineering approach involves the use of bioabsorb-
ble scaffolds to regenerate valve tissue. After resorption of
he scaffold, a valve composed only of the recipient’s tissues
ould remain (55). The technique has seen some success in
nimal models. Hoerstrup et al. (58) demonstrated that
apidly bioabsorbable scaffolds seeded with myofibroblasts
nd endothelial cells implanted in the pulmonic position in
Figure 10 Changes in Hemodynamic Function Over 4 Months
Maximum systolic gradient (A), mean gradient (B), and effective orifice area
(C) at time of implantation (t  0) and after 4 months (t  4) in vivo.
Reprinted, with permission, from Sutherland et al. (63).Tambs functioned for up to 5 months with microstructure,
echanical properties, and extracellular matrix formation
hat resembled normal valves.
ercutaneous valve replacement. Percutaneous aortic
alve replacement is emerging as a viable technique in
atients with severe aortic stenosis and multiple comorbidi-
ies that might preclude open valve replacement. Andersen
t al. (59) carried out feasibility studies using transcatheter
xpandable aortic valves in an animal model; in 2002,
ribier et al. (60) reported the first successful human
mplantation using an antegrade approach. Both retrograde
rterial and transapical approaches have since been carried
ut in small groups. Reported procedural success rates are at
east 75%, with immediate improvement in valve area and
emodynamic parameters. Short term (2- to 6-month)
ollow-up studies have suggested that after-procedural car-
iac event rates are low (61,62). Improving techniques will
ikely broaden the patient population eligible for percuta-
eous valve replacement.
tem cells. Stem cells are increasingly being evaluated as
he source of cells for tissue-engineered heart valves due to
heir ability to differentiate into various cell types (55,63).
utherland et al. (63) used a biodegradable scaffold seeded
ith mesenchymal stem cells derived from sheep bone
arrow to create an autologous semilunar heart valve that
unctioned satisfactorily for more than 4 months (Fig. 10).
Figure 11 Macroscopic Appearance of Tissue-Engineered
Semilunar Heart Valve Before Implantation
Valve viewed from below with leaflet free margins apposed in closed position
(A) and viewed in profile (B) with arrows outlining 1 sinus of Valsalva. Echocar-
diograms of implanted valve in short (C) and long (D) axes, in same approxi-
mate orientation as macroscopic images (A, B). Reprinted, with permission,
from Sutherland et al. (63).he valves were found to remodel in vivo, creating
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Degenerative Aortic Valve Disease September 25, 2007:1205–13ellular phenotypes and structural organization that
trongly mirrored those of native valves (Fig. 11) (63).
issue engineering, aided by emerging stem cell technol-
gy, holds immense potential for the treatment of valvu-
ar heart disease.
onclusions
egenerative aortic valve disease is a highly prevalent
isease associated with significant morbidity and mortality.
hough it displays a similar risk factor profile and histopa-
hology as atherosclerosis, DAVD is increasingly being
ecognized as a unique process. Elucidation of the cellular
nd molecular pathogenesis of degenerative valve disease has
rovided a basis for future therapeutic interventions to delay
r prevent its progression.
eprint requests and correspondence: Dr. Valentin Fuster, Zena
nd Michael A. Wiener Cardiovascular Institute, The Mount
inai School of Medicine, One Gustave L. Levy Place, Box 1030,
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